Office of Diversion Control, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

February

Noramco, Inc. (February 12, 2016)

60-Day Notice (Extension): Report of Mail Order Transactions (February 9, 2016)

Final Rule: Table of Excluded Nonnarcotic Products: Vicks® VapoInhaler® (February 8, 2016)

Final Rule: Table of Excluded Nonnarcotic Products: Nasal Decongestant Inhaler/Vapor Inhaler (February 8, 2016)

Proposed Rule: Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA into Schedule I (February 5, 2016)

Final Order: Temporary Placement of the Synthetic Cannabinoid MAB-CHMINACA Into Schedule I (February 5, 2016)

Final Order: Extension of Temporary Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA in Schedule I of the Controlled Substances Act (February 5, 2016)

Louis Watson, M.D.; Decision and Order (February 4, 2016)

David W. Bailey, M.D.; Decision and Order (February 4, 2016)

Kenneth H. Bull, M.D.; Decision and Order (February 4, 2016)

Pharmacore, Inc. (February 4, 2016)


January 2016

30-Day Notice (Extension): Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local Government) Crime Laboratories (January 28, 2016)

Final Rule: Self-Certification and Employee Training of Mail-Order Distributors of Scheduled Listed Chemical Products (January 25, 2016)

Johnson Matthey, Inc. (January 21, 2016)

Irwin August, D.O.; Decision and Order (January 20, 2016)

Siegfried USA, LLC (January 19, 2016)

Lipomed, Inc. (January 19, 2016)

American Radiolabeled Chemicals, Inc. (January 19, 2016)

Apertus Pharmaceuticals (January 19, 2016)

Rhodes Technologies (January 19, 2016)

Cambridge Isotope Lab (January 15, 2016)

60-Day Notice (Extension): Renewal Application for Registration Under Domestic Chemical Diversion Control Act of 1993 DEA Forms 510, 510A (January 15, 2016)

60-Day Notice (Extension): Annual Reporting for Manufacturers of Listed Chemicals (January 12, 2016)

Sharp Clinical Services, Inc. (January 11, 2016)

Myoderm (January 11, 2016)

Hospira (January 11, 2016)

Noramco, Inc. (January 11, 2016)

Chattem Chemicals Inc. (January 11, 2016)

Alltech Associates, Inc. (January 11, 2016)

IRIX Manufacturing, Inc. (January 11, 2016)

AMPAC Fine Chemicals LLC (January 11, 2016)


December 2015

Johnson Matthey, Inc. (December 29, 2015)

Almac Clinical Services Incorp (ACSI) (December 24, 2015)

Alltech Associates, Inc. (December 24, 2015)

Fisher Clinical Services, Inc. (December 17, 2015)

Johnson Matthey, Inc. (December 17, 2015)

National Center for Natural Products Research (NIDA MPROJECT) (December 17, 2015)

Austin Pharma LLC (December 17, 2015)

Final Rule: Placement of Eluxadoline Into Schedule IV; Correction (December 17, 2015)

30-Day Notice (Extension): Application for Registration Renewal; DEA Forms 224, 224A (December 11, 2015)

Cody Laboratories, Inc. (December 10, 2015)

Mylan Pharmaceuticals, Inc. (December 10, 2015)

Cambrex Charles City (December 8, 2015)

Cody Laboratories, Inc. (December 8, 2015)

Johnson Matthey Pharmaceutical Materials, Inc. (December 8, 2015)

AMRI Rensselaer, Inc. (December 8, 2015)

Mylan Technologies, Inc. (December 3, 2015)

Meridian Medical Technologies (December 3, 2015)

Mylan Pharmaceuticals, Inc. (December 3, 2015)

Fresenius Kabi USA, LLC (December 3, 2015)

United States Pharmacopeial Convention (December 3, 2015)

Akorn, Inc. (December 3, 2015)

Catalent CTS, LLC (December 3, 2015)

Organix, Inc. (December 3, 2015)

Noramco, Inc. (December 3, 2015)

Navinta, LLC (December 3, 2015)


November

Daniel A. Glick, D.D.S.; Decision and Order (November 30, 2015)

William Mikaitis, M.D.; Decision and Order (November 25, 2015)

VHG Labs DBA LGC Standards Warehouse (November 25, 2015)

Mark William Andrew Holder, M.D.; Decision and Order (November 16, 2015)

Final Rule: Placement of Eluxadoline Into Schedule IV; Correction (November 16, 2015)

Proposed Rule: Placement of Three Synthetic Phenethylamines Into Schedule I (November 13, 2015)

Final Order: Extension of Temporary Placement of Three Synthetic Phenethylamines in Schedule I (November 13, 2015)

Christina B. Paylan, M.D.; Decision and Order (November 12, 2015)

Perry County Food & Drug; Decision and Order (November 12, 2015)

Final Rule: Placement of Eluxadoline Into Schedule IV (November 12, 2015)

60-Day Notice (Extension): Application for Import Quota for Ephedrine, Pseudoephedrine, and Phenylpropanolamine DEA Form 488 (November 2, 2015)


October

Table of Excluded Nonnarcotic Products: Nasal Decongestant Inhaler/Vapor Inhaler (October 27, 2015)

Table of Excluded Nonnarcotic Products: Vicks® VapoInhaler® (October 27, 2015)

Cody Laboratories, Inc. (October 21, 2015)

Halo Pharmaceutical, Inc. (October 21, 2015)

Cerilliant Corporation (October 21, 2015)

Sigma-Aldrich International GMBH—Sigma Aldrich Co LLC (October 21, 2015)

Chattem Chemicals, Inc. (October 21, 2015)

Cambrex Charles City (October 21, 2015)

Unither Manufacturing, LLC (October 13, 2015)

American Radiolabeled Chemicals, Inc. (October 13, 2015)

Cambridge Isotope Lab (October 13, 2015)

Apertus Pharmaceuticals (October 13, 2015)

60-Day Notice (Extension): Application for Registration Renewal DEA Forms 224, 224A (October 9, 2015)

Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016 (October 6, 2015)


September

Cerilliant Corporation (September 30, 2015)

Noramco, Inc. (September 30, 2015)

James Alvin Chaney, M.D.; Decision and Order (September 23, 2015)

Fresenius Kabi USA, LLC (September 23, 2015)

Fisher Clinical Services, Inc. (September 23, 2015)

Rhodes Technologies (September 23, 2015)

Wildlife Laboratories, Inc. (September 23, 2015)

Mallinckrodt LLC (September 23, 2015)

Chemtos, LLC (September 23, 2015)

Cedarburg Pharmaceuticals, Inc. (September 23, 2015)

Euticals, Inc. (September 23, 2015)

AMRI Rensselaer Inc. (September 23, 2015)

Brown’s Discount Apothecary, BC, Inc., and Bolling Apothecary, Inc.; Orders to Show Cause (September 23, 2015)

Chung-Kuang Chen, M.D.; Dismissal of Proceeding (September 21, 2015)

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015 (September 16, 2015)

Notice of Intent: Temporary Placement of the Synthetic Cannabinoid MAB-CHMINACA Into Schedule I (September 16, 2015)

Masters Pharmaceuticals, Inc.; Decision and Order (September 15, 2015)

Final Rule: Removal of [123I]Ioflupane From Schedule II of the Controlled Substances Act (September 11, 2015)

Chattem Chemicals Inc. (September 9, 2015)

Akorn, Inc. (September 9, 2015)

PCAS-Nanosyn, LLC (September 9, 2015)

Abbas E. Sina, M.D.; Decision and Order (September 2, 2015)

 

Emergency Disaster Relief
Got Drugs? Turn in your unused or expired medication for safe disposal here.
Alert! Extortion Scam

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Office of Diversion Control  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539